Baleivanualala Sakiusa C, Matanitobua Silivia, Soqo Vika, Smita Shayal, Limaono Josese, Sharma Sajnel C, Devi Swastika V, Boseiwaqa Lusiana V, Vera Numa, Kumar Silpa, Lalibuli Amele, Mailulu Josese, Wilson Donald, Samisoni Yvette, Crump John A, Ussher James E
Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin 9054, New Zealand.
College of Medicine, Nursing and Health Science, Fiji National University, Suva, Fiji.
Lancet Reg Health West Pac. 2024 May 29;47:101095. doi: 10.1016/j.lanwpc.2024.101095. eCollection 2024 Jun.
Carbapenem resistant organisms (CROs) such as (CR), (CR), (CR), and (CR) have been identified by the World Health Organization (WHO) as global priority pathogens. The dissemination of these pathogens and clonal outbreaks within healthcare facilities are of serious concern, particularly in regions with limited resources. In Fiji, where healthcare services are primarily provided by public hospitals, understanding the extent and nature of this problem is essential for the development of effective patient management, prevention interventions and control strategies.
CROs isolated from 211 (77.3%) non-sterile (urinary catheters, urine, sputum, wound swab, and endotracheal tube) and 62 (22.7%) normally sterile (blood, cerebrospinal fluid, intravascular catheter, and aspirates) body sites of 272 patients treated at the three major hospitals in Fiji, the Colonial War Memorial Hospital (CWMH), Lautoka Hospital (LTKH), and Labasa Hospital (LBSH), and outer peripheral health centres around Fiji, were analysed. Clinical and demographic patient data such as age, sex, admission diagnosis, admission and discharge dates, patient outcomes, date of death, start and end date of meropenem and colistin treatment were reviewed. These CRO isolates comprised , , , and , that were prospectively collected at the microbiology laboratory of CWMH and LBSH from January 2020 through August 2021 and at the LTKH from January 2020 to December 2021. In addition, 10 retrospectively stored CR isolates collected from patients at the CWMH from January through December 2019, were also included in the study. All isolates were characterised using mass spectrometry, antimicrobial susceptibility testing, and whole genome sequencing. Phylogenetic relationships among the CROs were assessed through core genome single nucleotide polymorphism (SNP) analysis. The CR isolates were also compared to the CR isolates from CWMH isolated in 2016/2017 and 2019, along with CR isolates obtained from Fijian patients admitted to New Zealand hospitals in 2020 and 2021 from our retrospective study.
Of 272 patients, 140 (51.5%) were male, the median (range) age of patients was 45 (<1-89) years, 161 (59.2%) were I-Taukei, 104 (38.2%) Fijians of Indian descent, and 7 (2.6%) were from other ethnic backgrounds. 234 (86.0%) of these 272 patients, had their first positive CRO sample collected ≥72 h following admission and the remaining 38 (14.0%) were isolated within 72 h following admission. Of the 273 CROs, 146 (53.5%) were collected at the CWMH, 66 (24.2%) LTKH, and 61 (22.3%) LBSH, while 62 (22.7%) were isolated from normally sterile sites and 211 (77.3%) from sites that are not sterile. Of 273 isolates, 131 (48.0%) were CR, 90 (33.0%) CR, 46 (16.8%) CR, and 6 (2.2%) CR. Of 131 CR, 108 (82.4%) were ST2, with three distinct clones, all encoding and , while clone 3 also encoded ; was associated with two copies of IS insertion element, forming the composite transposon Tn. The first two CR ST2 clones were genetically linked to those isolated at CMWH 2016 through 2019, while the third was genetically linked to isolates from Fijian patients admitted to New Zealand hospitals in 2020 and 2021. Of CR, 65 (72.2%) were ST773 and carried β-lactamase genes , , and . Of 10 retrospective CR isolates, all belonged to CR ST773 and carried , , and . Of 46 CR, 44 (95.7%) were ST410 and encoded on an IncX3 plasmid. Of 6 CR, 4 (66.7%) were ST16 and carried on an IncX3 plasmid. Other sequence types of CR (ST9, ST357, ST654, ST664), CR (ST25, ST374, ST499), CR (ST167), and CR (ST45, ST336) were also detected. Of those receiving meropenem treatment in the prospective study, 30 (57.7%) received it inappropriately. Of 272 patients, 65 (23.9%) died within the 30 days after first positive CRO isolation.
We identified nosocomial transmission of distinct clones of CR ST2, CR ST773, CR ST410, and CR ST16 within and between the three major hospitals in Fiji. Moreover, community onset infections associated with CR, CR, and CR were also detected. Of note, cross-border transmission of CR ST2 clone 3 strain between Fiji and New Zealand was also detected. These clones encoded an array of carbapenem resistance genes associated with mobile genetic elements, including plasmids, transposons, and integrative and conjugative elements, signifying their potential for increased mobility, further acquisition of resistance genes, and spread. Inappropriate use of meropenem was common. Of note, the majority of patients who died had acquired CRO during their hospital stay. These findings highlight the need for stringent IPC strategies focusing on catheter and ventilator management, meticulous wound care, rigorous sepsis control, consistent hand hygiene, effective use of disinfectants, and thorough sanitisation of both hospital environments and medical equipment in the three major hospitals in Fiji. Additionally, diligent surveillance of AMR and robust antimicrobial stewardship are crucial for effectively managing nosocomial infections.
This project was funded by the Otago Medical School Foundations Trust (Dean's Bequest Fund) and a Fiji National University seed grant. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
耐碳青霉烯类微生物(CROs),如耐碳青霉烯类肺炎克雷伯菌(CR-Kp)、耐碳青霉烯类大肠埃希菌(CR-Ec)、耐碳青霉烯类鲍曼不动杆菌(CR-Ab)和耐碳青霉烯类铜绿假单胞菌(CR-PA),已被世界卫生组织(WHO)确定为全球重点病原体。这些病原体在医疗机构内的传播和克隆性暴发令人严重担忧,尤其是在资源有限的地区。在斐济,医疗服务主要由公立医院提供,了解这一问题的严重程度和性质对于制定有效的患者管理、预防干预措施和控制策略至关重要。
对从斐济三家主要医院,即殖民地战争纪念医院(CWMH)、劳托卡医院(LTKH)和拉巴萨医院(LBSH)以及斐济周边地区医疗中心接受治疗的272例患者的211个(77.3%)非无菌(导尿管、尿液、痰液、伤口拭子和气管内导管)和62个(22.7%)通常无菌(血液、脑脊液、血管内导管和吸出物)身体部位分离出的CROs进行了分析。回顾了患者的临床和人口统计学数据,如年龄、性别、入院诊断、入院和出院日期、患者预后、死亡日期、美罗培南和黏菌素治疗的开始和结束日期。这些CRO分离株包括CR-Kp、CR-Ec、CR-Ab和CR-PA,它们是在2020年1月至2021年8月期间在CWMH和LBSH的微生物实验室以及2020年1月至2021年12月期间在LTKH前瞻性收集的。此外,还纳入了2019年1月至12月从CWMH患者中回顾性收集的10株CR分离株。所有分离株均采用质谱分析、药敏试验和全基因组测序进行鉴定。通过核心基因组单核苷酸多态性(SNP)分析评估CROs之间的系统发育关系。还将CR分离株与2016/2017年和2019年在CWMH分离的CR分离株以及我们回顾性研究中2020年和2021年从斐济患者中获得的新西兰医院的CR分离株进行了比较。
在272例患者中,140例(51.5%)为男性,患者的年龄中位数(范围)为45(<1-89)岁,161例(59.2%)为伊陶凯人,104例(38.2%)为印度裔斐济人,7例(2.6%)来自其他种族背景。这272例患者中,234例(86.0%)在入院≥72小时后采集到首个阳性CRO样本,其余38例(14.0%)在入院72小时内分离出。在273株CRO中,146株(53.5%)在CWMH采集,66株(24.2%)在LTKH采集,61株(22.3%)在LBSH采集,而62株(22.7%)从通常无菌部位分离,211株(77.3%)从非无菌部位分离。在273株分离株中,131株(48.0%)为CR-Kp,90株(33.0%)为CR-Ec,46株(16.8%)为CR-Ab,6株(2.2%)为CR-PA。在131株CR-Kp中,108株(82.4%)为ST2,有三个不同的克隆,均编码blaKPC和blaNDM,而克隆3还编码blaOXA-48;blaKPC与两个IS插入元件拷贝相关联,形成复合转座子Tn。前两个CR-Kp ST2克隆在基因上与2016年至2019年在CMWH分离的克隆相关联,而第三个在基因上与2020年和2021年从斐济患者中分离出的新西兰医院的分离株相关联。在CR-Ec中,65株(72.2%)为ST773,并携带β-内酰胺酶基因blaCTX-M、blaTEM和blaSHV。在10株回顾性CR-Ec分离株中,均属于CR-Ec ST773,并携带blaCTX-M、blaTEM和blaSHV。在46株CR-Ab中,44株(95.7%)为ST410,并在IncX3质粒上编码blaOXA-58。在6株CR-PA中,4株(66.7%)为ST16,并在IncX3质粒上携带blaVIM。还检测到其他CR-Kp(ST9、ST357、ST654、ST664)、CR-Ec(ST25、ST374、ST499)、CR-Ab(ST167)和CR-PA(ST45、ST336)的序列类型。在前瞻性研究中接受美罗培南治疗的患者中,30例(57.7%)使用不当。在272例患者中,65例(23.9%)在首次阳性CRO分离后30天内死亡。
我们在斐济的三家主要医院内部和之间发现了CR-Kp ST2、CR-Ec ST773、CR-Ab ST410和CR-PA ST16不同克隆的医院内传播。此外,还检测到与CR-Kp、CR-Ec和CR-Ab相关的社区发病感染。值得注意的是,还检测到CR-Kp ST2克隆3菌株在斐济和新西兰之间的跨境传播。这些克隆编码了一系列与移动遗传元件相关的碳青霉烯耐药基因,包括质粒、转座子和整合与接合元件,表明它们具有增加移动性、进一步获得耐药基因和传播的潜力。美罗培南的使用不当很常见。值得注意的是,大多数死亡患者在住院期间感染了CRO。这些发现凸显了在斐济的三家主要医院中需要采取严格的感染预防与控制(IPC)策略,重点是导管和呼吸机管理、细致的伤口护理、严格的败血症控制、持续的手部卫生、有效使用消毒剂以及对医院环境和医疗设备进行彻底消毒。此外,对耐药性的勤勉监测和强有力的抗菌药物管理对于有效管理医院感染至关重要。
本项目由奥塔哥医学院基金会信托基金(院长遗赠基金)和斐济国立大学种子基金资助。该研究的资助者在研究设计、数据收集、数据分析、数据解释或报告撰写方面没有任何作用。